^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

FOXA1 overexpression

i
Other names: FOXA1, Forkhead Box A1, Hepatocyte Nuclear Factor 3-Alpha, Forkhead Box Protein A1, Transcription Factor 3A, HNF-3-Alpha, HNF-3A, TCF-3A, HNF3A, TCF3A, Hepatocyte Nuclear Factor 3 Alpha
Entrez ID:
Related biomarkers:
1year
LPCAT1 is transcriptionally regulated by FOXA1 to promote breast cancer progression and paclitaxel resistance. (PubMed, Oncol Lett)
Furthermore, FOXA1 overexpression attenuated the effects of LPCAT1 knockdown on cells, indicating that FOXA1 transcriptionally regulates LPCAT1. In summary, the present study reveals that LPCAT1 is transcriptionally regulated by FOXA1, which influences breast cancer cell proliferation, metastatic potential and PTX resistance.
Journal
|
FOXA1 (Forkhead Box A1) • LPCAT1 (Lysophosphatidylcholine Acyltransferase 1)
|
FOXA1 overexpression
|
paclitaxel
over1year
Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC) (SABCS 2022)
TF binding motif at the shared SEs (mapped by H3K27ac ChIP-seq) between MCF7-parental (P) cells with ectopic FOXA1 overexpression (OE) and the endogenous FOXA1-amplifed tamoxifen-resistant (TamR) cells was analyzed by HOMER... Using SE-oriented integrative bioinformatics, we identified KLF4 as a potential novel target in the FOXA1/AP-1 transcriptional axis. As KLF4 binding motif resides in the unique ER-bound SEs of TamR cells, KLF4 likely forms an auto- regulated loop amplifying CRC in transcriptional reprogramming, among which the PYGB/glycogen metabolic pathway merits further investigation in endocrine-resistant ER+ disease.
PD(L)-1 Biomarker • IO biomarker
|
ER (Estrogen receptor) • PD-1 (Programmed cell death 1) • KLF4 (Kruppel-like factor 4) • FOXA1 (Forkhead Box A1) • JUN (Jun proto-oncogene)
|
ER positive • FOXA1 overexpression
|
tamoxifen
almost3years
FOXA1 overexpression suppresses interferon signaling and immune response in cancer. (PubMed, J Clin Invest)
These findings were also validated in bladder cancer expressing high level FOXA1. FOXA1 overexpression could be a prognostic factor to predict therapy resistance and a viable target to sensitize luminal prostate, breast and bladder cancer to immuno- and chemotherapy.
Journal • IO biomarker
|
ER (Estrogen receptor) • AR (Androgen receptor) • FOXA1 (Forkhead Box A1) • STAT2 (Signal transducer and activator of transcription 2)
|
ER positive • AR positive • FOXA1 overexpression